CompanDX

The collaboration draws on ResearchDx's ability to design, produce, and validate tests, and CompanDx's Distiller platform to deliver small composite biomarker signatures from complex data of high dimensionality.

Under the terms of the multi-year agreement, the partners will advance diagnostic tests, from biomarker discovery to test validation, applying CompanDx's Risk Distiller bioinformatics tool and CRL's CLIA-certified laboratory services.

The partners said they will collaborate on the development of biomarker panels and companion diagnostics for pharmaceutical, biotech, and academic clients worldwide.

The 31-gene signature, used to predict the time to cancer metastasis after initial surgery and biopsy, has been validated by CompanDX researchers in four different datasets, according to the company.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

Nature News writes that researchers are still wrangling over the role of the p-value.

In Nature this week: paternal age associated with de novo mutations in children, and more.